The cholesterol drug Vytorin, sold by Merck & Schering-Plough, failed to meet the goal of improving outcomes any better than a placebo, according to a new study. The new data did little in the way of removing doubt from a previous study in January that suggested the combination drug failed to work any better than that of the cheaper generic statin. Vytorin did lower LDL cholesterol. More study is planned.